Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for CDNA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 280.59M
March 31, 2026 11.06M
December 31, 2025 -34.91M
September 30, 2025 12.35M
June 30, 2025 23.40M
March 31, 2025 1.325M
December 31, 2024 -2.111M
September 30, 2024 -14.41M
June 30, 2024 -11.63M
March 31, 2024 27.66M
December 31, 2023 41.37M
September 30, 2023 -1.498M
June 30, 2023 15.35M
March 31, 2023 -14.77M
December 31, 2022 2.475M
September 30, 2022 -75.74M
June 30, 2022 0.79M
March 31, 2022 -156.03M
December 31, 2021 -7.782M
September 30, 2021 20.20M
June 30, 2021 16.21M
March 31, 2021 19.08M
December 31, 2020 -90.47M
September 30, 2020 -4.236M
June 30, 2020 -3.98M
Date Value
March 31, 2020 -1.704M
December 31, 2019 -1.342M
September 30, 2019 -3.515M
June 30, 2019 -17.18M
March 31, 2019 -0.543M
December 31, 2018 -0.96M
September 30, 2018 -0.614M
June 30, 2018 -5.601M
March 31, 2018 -0.754M
December 31, 2017 -5.061M
September 30, 2017 -1.009M
June 30, 2017 0.01M
March 31, 2017 -0.104M
December 31, 2016 0.077M
September 30, 2016 -0.351M
June 30, 2016 -20.73M
March 31, 2016 -0.109M
December 31, 2015 -0.076M
September 30, 2015 -0.39M
June 30, 2015 -0.369M
March 31, 2015 -0.364M
December 31, 2014 -0.594M
September 30, 2014 -0.199M
June 30, 2014 -0.521M
March 31, 2014 -0.019M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Natera, Inc. -63.43M
Caris Life Sciences, Inc. -122.19M
Myriad Genetics, Inc. -3.20M
BioRestorative Therapies, Inc. 0.9684M
Exagen, Inc. -0.543M